Jie Yang
China Medical University (PRC)
4 Papers
5 Citations
Jie Yang is an academic researcher from China Medical University (PRC). The author has contributed to research in topics: Metastasis & Breast cancer. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Association of human breast cancer CD44-/CD24- cells with delayed distant metastasis.
Xinbo Qiao,Yixiao Zhang,Lisha Sun,Qingtian Ma,Jie Yang,Liping Ai,Jinqi Xue,Guanglei Chen,Hao Zhang,Ce Ji,Xi Gu,Haixin Lei,Yongliang Yang,Caigang Liu +13 more
TL;DR: In this article, the frequency of CD44-/CD24- breast cancer cells in 576 tissue specimens for associations with clinicopathological features and metastasis and investigated the underlying molecular mechanisms.
20
Prognostic significance of GSTP1 in patients with triple negative breast cancer
Guanglei Chen,Hao Zhang,Lisha Sun,Yanlin Jiang,Zhen Xu,Huizi Gu,Hong Xu,Jie Yang,Yining Wang,Tiantian Xu,Yingchao Zhang,Caigang Liu +11 more
TL;DR: Tumors with high GSTP1 protein expression were independently associated with low clinical stages in TNBC patients in China and may be a novel prognosis marker for TNBC Patients in China.
6
FSIP1 regulates autophagy in breast cancer
Caigang Liu,Lisha Sun,Jie Yang,Tong Liu,Yongliang Yang,Se-Min Kim,Xunyan Ou,Yining Wang,Li Sun,Mone Zaidi,Maria I. New,Tony Yuen,Qiyong Guo +12 more
TL;DR: It is reported that FSIP1 positively regulates the proliferation and invasion of triple-negative breast cancer cells, and its silencing promotes drug resistance by inducing autophagy, by reducing mitochondrial biogenesis, and by enhancing AMP-activated protein kinase activation.
FSIP1 binds HER2 directly to regulate breast cancer growth and invasiveness.
Tong Liu,Hao Zhang,Li Sun,Danyu Zhao,Peng Liu,Meisi Yan,Neeha Zaidi,Sudeh Izadmehr,Animesh Gupta,Wahid Abu-Amer,Minna Luo,Jie Yang,Xunyan Ou,Yining Wang,Xuefeng Bai,Yan Wang,Maria I. New,Mone Zaidi,Tony Yuen,Caigang Liu +19 more
TL;DR: Fibrous sheath interacting protein 1 is a signaling partner to HER2, and that FSIP inhibition reduces cell growth and invasiveness in HER2-positive breast cancer cells, and may become a potential target for breast cancer therapy.